Skip to main content
. 2013 Dec 18;14(1):139. doi: 10.1186/1465-9921-14-139

Figure 1.

Figure 1

Overall survival of metastatic NSCLC patients. Patients received either systemic therapy, palliative local treatment without systemic therapy or no anti-cancer treatment. Median survival rates were 8.7, 2.9, and 1.3 months respectively (p < 0.001).